Supported primarily by solid first-quarter 2026 results, shares of Morgan Stanley MS have gained 13.2% so far this year, outperforming the S&P 500 Index’s 9.7% growth and the industry’s 2.2% decline.

Counterfeit medicines are a fundamental security problem. Counterfeiting medication poses a tremendous threat to patient safety, public health, and the economy in developed and less developed ...